VANCOUVER, Nov. 6, 2018 /CNW/ - Sirona Biochem Corp.
(TSX-V: SBM) (FSE: ZSB) (the "Company") reported today the
successful launch of the clinical trial for skin-lightener TFC-1067
with leading dermatologist Dr. Zoe
Draelos.
In September, Sirona reported that the Company was awaiting
final results from the second clinical trial for the Human Repeat
Insult Patch Test (HRIPT). This test was performed on 110 people to
assess safety of TFC-1067. The data confirmed TFC-1067 as a
non-sensitizer, providing the final support needed for toxicologist
approval.
Following completion of the preliminary studies and toxicologist
approval, the Company has begun the enrollment process for the
clinical trial. All material, including the formulated TFC-1067
cream, has been delivered to the clinical-trial center in
North Carolina and final
International Review Board approval is pending.
Once patients have been enrolled, the twelve-week assessment of
TFC-1067 will begin under the supervision of Dr. Draelos, who has
conducted clinical trials for many top pharmaceutical companies
worldwide. The Company looks forward to using the results to
further and solidify discussions with partners in North America and Asia, as final confirmation of TFC-1067's
safety and efficacy as a skin-lightening agent.
"This clinical trial marks a major milestone for Sirona Biochem
and its scientific team," said Dr. Howard
Verrico. "With the anticipated start of the clinical trial
for Sirona's SGLT-2 inhibitor, TFC-039, by partner Wanbang
Biopharmaceuticals Co. Ltd. this year, we will have two compounds
simultaneously in clinical trials. This highlights the strength of
Sirona's platform technology in creating novel compounds for both
therapeutic and cosmetic indications with excellent potential for
full commercialization."
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and
research dermatologist based in High
Point, North Carolina. Dr. Draelos, supported by a team of
highly skilled scientists, is the head of the Dermatology
Consulting Services (DCS) research organization, aimed at
facilitating research, consulting and communication services to the
pharmaceutical and cosmetic industries. The clinical trial center
runs assessments on different skin, hair and nail conditions, such
as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been
recognized many times over the years for her cutting-edge research,
including the lifetime achievement award from Health Beauty America
and the Society of Cosmetic Chemists. A pioneer in the field of
cosmetic dermatology, Dr. Draelos continues to work with lead
cosmetic and pharmaceutical companies as well as furthering her own
research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of
Dermatology and is a Consulting Professor of Dermatology at
Duke University. She has authored over
300 articles, 8 books and has shared her expertise across different
media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
__________________________
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.